Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Platelets acquire a secretion defect after high-dose chemotherapy.

T J Panella1, W Peters, J G White

  • 1Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710.

Cancer
|April 15, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of tissue transglutaminase on the solubility of proteins containing expanded polyglutamine repeats.

Journal of neurochemistry·2004
Same author

Calcium regulates S-nitrosylation, denitrosylation, and activity of tissue transglutaminase.

Biochemistry·2001
Same author

Reversible shear-mediated platelet dysfunction during cardiac surgery as assessed by the PFA-100 platelet function analyzer.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis·2001
Same author

Hemostatic effects of antithrombin III supplementation during cardiac surgery: results of a prospective randomized investigation.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis·2001
Same author

Localization of tissue transglutaminase in human carotid and coronary artery atherosclerosis: implications for plaque stability and progression.

Laboratory investigation; a journal of technical methods and pathology·2001
Same author

Tamoxifen inhibits angiogenesis in estrogen receptor-negative animal models.

Clinical cancer research : an official journal of the American Association for Cancer Research·2000

High-dose chemotherapy (HDC) can cause acquired platelet defects, impairing aggregation and secretion. This platelet dysfunction may increase the risk of bleeding complications in patients undergoing autologous bone marrow transplantation (ABMT).

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • High-dose chemotherapy (HDC) followed by autologous bone marrow transplantation (ABMT) is a critical treatment for certain cancers.
  • Patients undergoing HDC-ABMT are at risk for life-threatening hemorrhagic myocarditis.
  • An acquired platelet defect has been suspected as a contributing factor to these hemorrhagic complications.

Purpose of the Study:

  • To investigate whether high-dose chemotherapy (HDC) induces an acquired defect in platelet function.
  • To evaluate the impact of HDC on platelet aggregation and release mechanisms.
  • To determine if this defect precedes thrombocytopenia and contributes to bleeding risks.

Main Methods:

  • Platelet aggregation and release assays were performed on ten patients post-HDC.

Related Experiment Videos

  • Platelet function was assessed using various agonists including adenosine diphosphate (ADP), arachidonic acid, and collagen.
  • Electron microscopy was used to examine platelet morphology, and adenosine triphosphate (ATP) release was quantified.

    • Main Results:

    • HDC was associated with impaired secondary platelet aggregation induced by multiple agonists.
    • Platelets showed normal morphology and granule content, but significantly reduced adenosine triphosphate (ATP) release (<20% of normal).
    • The acquired platelet defect was observed before the development of thrombocytopenia.

    Conclusions:

    • High-dose chemotherapy induces an acquired abnormality in platelet secretion and aggregation.
    • This HDC-induced platelet defect may play a significant role in the hemorrhagic complications observed after autologous bone marrow transplantation.
    • The findings highlight the need for monitoring platelet function in patients receiving HDC-ABMT.